Skip to main content

ESP prostheses training program

Press release        Ecully, July 11, 2024 – 6.30 p.m.

Spineway organizes hands-on training on total disc replacement with its ESP prostheses at IRCAD in Strasbourg

The Spineway Group, a specialist in innovative implants for the treatment of severe spine disorders, organized a hands-on training workshop entitled “Hands-on Total Disc Replacement featuring ESP technology” at the Institut de Recherche contre les Cancers de l’Appareil Digestif (IRCAD) in Strasbourg on June 28, 2024. During the event, Spineway’s ESP prostheses (cervical and lumbar) were presented to 25 surgeons and professionals, with a presentation of the products, their indications and two surgical approach sessions.

The training workshops took place at IRCAD in Strasbourg, renowned for the quality of its facilities and were led by renowned surgeons, Dr. Biren Desai (Germany), Dr. Olivier Ricart (Luxembourg) and Pr. Marc Antoine Rousseau (Paris).
During these hands-on workshops, Spineway had three tables dedicated to training surgeons in total disc replacement, with its cervical (CP-ESP) and lumbar (LP-ESP) prostheses.

 

These training courses, highly appreciated by surgeons, allow professionals to study and practice different surgical approaches in order to learn or perfect their technique. The workshop was attended by nine international surgeons who were divided into groups of three on each table to ensure optimal training time for each participant. Participants came from Spain, Malaysia, Greece, the United Arab Emirates, Tunisia, France and Germany, reflecting the international scope of the event. Some were accompanied by their distributors, bringing the total number of participants to 25. Spineway teams were also present, including Stéphane Le Roux (CEO), Fabrice Paccagnella (Sales Director), Mélody Ourdouillié (Medical Education), Loïc Aden (Product Manager), Inès Khaoua and Yiyi Li (Sales).

The event was an opportunity to create or strengthen ties between new and future users of Spineway products and training surgeons, while supporting the Group’s distributors in their training initiatives.

In line with its strategy, Spineway aims to develop and reinforce the number of such training courses in order to strengthen its reputation among spine surgeons. The Group confirms its aim of becoming a major player in less invasive spine treatments.

Next event:
July 15, 2024 – H1 2024 revenue

SPINEWAY IS ELIGIBLE FOR PEA-SME (EQUITY SAVINGS PLANS FOR SMES)
Find out all about Spineway at www.spineway.com

This press release has been prepared in both English and French. In case of discrepancies, the French version shall prevail.

Spineway designs, manufactures and markets innovative implants and surgical instruments for treating severe disorders of the spinal column.
Spineway has an international network of independent distributors and derives more than 70% of its revenue from exports.
ISIN: FR001400BVK2 – ALSPW        

Contacts:

SPINEWAY GROUP

Shareholder-services line

Available Tuesday through Thursday

+33 (0)806 706 060

Eligible PEA / PME

ALSPW

Euronext Growth

AELIUM

Finance & Ciommunication

Investor relations

Solène Kennis

spineway@aelium.fr

Attachment

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.